索利那新在膀胱结石腔内碎石治疗中应用.docVIP

索利那新在膀胱结石腔内碎石治疗中应用 　　【摘要】 目的 观察评测膀胱结石合并膀胱过度活动症（OAB）患者行腔内碎石术前、术后早期使用索利那新的临床疗效和不良反应。方法 60例采用单纯经尿道膀胱结石腔内碎石取石术的膀胱结石合并OAB患者， 随机分为实验组与对照组， 每组30例。实验组于术晨开始口服琥珀酸索利那新片5 mg/次， 1次/d， 口服至拔除导尿管后3 d；对照组予以常规治疗。观察比较两组患者术后膀胱痉挛、尿急、尿频、急迫性尿失禁情况。结果 两组患者手术均一次成功， 无结石残留。实验组术后膀胱痉挛次数、持续时间明显少于对照组， 差异有统计学意义（P0.05）；夜尿次数、24 h平均尿量多于对照组， 差异有统计学意义（P0.05）。术后两组24 h平均尿急次数、急迫性尿失禁次数及排尿次数明显少于术前， 且实验组优于对照组， 差异具有统计学意义（P0.05）。结论 膀胱结石合并OAB患者行腔内碎石术前、术后早期使用索利那新， 对缓解术后膀胱痉挛、尿急、尿频、急迫性尿失禁等症状有良好的效果， 值得临床推广应用。 　　【关键词】 索利那新；膀胱结石；膀胱过度活动症 　　DOI：10.14163/j.cnki.11-5547/r.2016.07.001 　　Application of solifenacin in intracavity lithotripsy for cystolith HONG Hui-bin， WANG Le-hao. Department of Urinary Surgery， Guangdong Shantou City Second People’s Hospital， Shantou 515011， China 　　【Abstract】 Objective To observe and evaluate clinical effect and adverse reactions by early preoperative and postoperative application of solifenacin in intracavity lithotripsy for cystolith complicated with overactive bladder （OAB）. Methods A total of 60 patients of cystolith complicated with OAB receiving simple transurethral intracavity lithotripsy were randomly divided into experimental group and control group， with 30 cases in each group. The experimental group received succinic acid solifenacin tablet by 5 mg/time once a day through oral administration till 3 d after catheter extubation. The control group received conventional treatment. Observations were made on postoperative cystospasm， urgent urination， frequent micturition， and urge incontinence. Results Both groups received successful operation， without residual stones. The experimental group had obviously less postoperative cystospasm times and last time than the control group， and their difference had statistical significance （P 　　【Key words】 Solifenacin； Cystolith； Overactive bladder 　　膀胱结石患者因结石对膀胱的刺激， 可出现尿急、尿频等OAB症状， 甚至出现急迫性尿失禁。手术去除结石后， 部分患者仍会存在上述症状。琥珀酸索利那新是目前临床上用于治疗OAB的新一代高选择性胆碱能受体M3阻滞剂[1]。作者选取60例膀胱结石合并OAB患者单纯行经尿道膀胱结石腔内碎石取石术， 并分组进行治疗， 观察索利那新对术后OAB症状的治疗效果。现报告如下。 　　1 资料与方法